Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent...
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
About this item
Full title
Author / Creator
Publisher
Germany: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Germany: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD) by 44% and in diabetic CVD patients by 57% on top of statins. A phase III trial, BETonMACE, is currently assessing apabetalone's...
Alternative Titles
Full title
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6626370
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6626370
Other Identifiers
ISSN
1868-7075,1868-7083
E-ISSN
1868-7083,1868-7075
DOI
10.1186/s13148-019-0696-z
